KCT0006822招募中未知
Investigation on the individualized starting dose of 6-mercaptopurine based on pharmacogenetics
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 1?(Year) 至 20?(Year)（—）
- 性别
- All
入选标准
- •1. 1 year < age < 21 years old
- •2. Newly diagnosed pediatric acute lymphoblastic leukemia patients who achieved complete remission through remission induction therapy
- •3. Patients who have pharmacogenetics results and start maintenance therapy
排除标准
- •1. Patients who plan to undergo hematopoietic stem cell transplantation
- •2. Patients who have relapsed
研究者
相似试验
已完成
不适用
Phase I study to optimize the safe starting dose of weekly paclitaxelhead and neck cancerJPRN-UMIN000020357Kanazawa University24
已完成
不适用
A PHASE 0 SINGLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS/-DYNAMICS AND SPECIFIC TARGETING PROPERTIES OF 124-I-F8IL10 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INFLAMMATORY BOWEL DISEASErheumatoid arthritis and inflammatory bowel disease100179691000381610023213NL-OMON39620Vrije Universiteit Medisch Centrum10
尚未招募
1 期
DREAMM-9: Phase 1 Study of Belantamab Mafodotin Plus Standard of care in NewlyDiagnosed Multiple Myeloma patientsCTRI/2024/03/064587GlaxoSmithKline Research Development Limited
已完成
2 期
Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy * a single arm phase II studyNL-OMON47267niversitair Medisch Centrum Utrecht53
尚未招募
1 期
Safety and Tolerability of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to CarfilzomibCancerACTRN12621001458820South Western Sydney Local Health District36